Neuronetics, Inc. (STIM) - Form 8-K Summary
Business Context and Reporting Period
Neuronetics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 11, 2026. The filing announces financial results for the three and six months ended June 30, 2026, and includes a presentation to investors. The company's principal executive offices are located in Malvern, PA.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release (Exhibit 99.1) and investor presentation (Exhibit 99.2), which are incorporated by reference but not detailed in the body of this 8-K.
Material Changes and Comparisons
The filing does not explicitly state material changes versus prior periods within the text provided. Investors must refer to the attached press release for comparative financial data.
Guidance, Outlook, and Risks
The filing includes extensive forward-looking statements regarding business outlook, revenue, expenses, and growth for the remainder of fiscal year 2026. Management highlights significant risks and uncertainties, including:
- The impact of a transaction with Greenbrook TMS Inc. on business relationships.
- History of losses and the ability to achieve or sustain profitable operations.
- Reliance on the NeuroStar Advanced Therapy System for revenue generation.
- Reimbursement availability from third-party payors and physician/patient demand.
- Competitive technologies, product defects, and intellectual property protection.
- Regulatory developments in the U.S. and other jurisdictions.
- Credit facility terms, existing cash balance, and the ability to continue as a going concern.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash flow figures for the period ended June 30, 2026.
- Verify the details of the transaction with Greenbrook TMS Inc. and its specific impact on operations.
- Assess the company's current cash balance and runway to determine going concern status.
- Examine the terms of the existing credit facility and any covenants that may be at risk.
- Confirm the status of reimbursement coverage for the NeuroStar Advanced Therapy System.